Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7188102 | 1.00 | DPP4 (0.52) | DPP4PTPN1ABCG2MAOBCYP1A1 | |
| SCHEMBL7193971 | 0.96 | DPP4 (0.48) | DPP4PTPN1ABCG2MAOBCYP1A1 | |
| SCHEMBL7192562 | 0.95 | PLA2G2A (0.50) | DPP4PTPN1ABCG2PLA2G2ABCHE | |
| SCHEMBL7193944 | 0.94 | DPP4 (0.50) | DPP4PTPN1ABCG2MAOBCYP1A1 | |
| SCHEMBL7193951 | 0.94 | DPP4 (0.50) | DPP4PTPN1ABCG2MAOBCYP1A1 | |
| SCHEMBL7195708 | 0.90 | DPP4 (0.49) | DPP4PTPN1ABCG2 | |
| SCHEMBL7195711 | 0.90 | DPP4 (0.49) | DPP4PTPN1ABCG2 | |
| SCHEMBL7188125 | 0.88 | MAOB (0.53) | DPP4PTPN1ABCG2MAOBCYP1A1 | |
| SCHEMBL7188130 | 0.88 | MAOB (0.53) | DPP4PTPN1ABCG2MAOBCYP1A1 | |
| SCHEMBL7193939 | 0.86 | SMPD1 (0.50) | DPP4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | DPP4 1733/4885PTPN1 872/4885ABCG2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.